Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

The primary treatment option for non-small cell lung cancer (NSCLC) adenocarcinoma (ADC) with activating epidermal growth factor receptor (EGFR) mutation is EGFR tyrosine kinase inhibitor (TKI). After a certain period of treatment with EGFR TKI, acquired resistance emerges most frequently with a secondary mutation, p.T790M (36-50%), followed by MET amplification (10-19%). Interestingly, up to 3-5% of patients experience histological transformation into small cell lung cancer (SCLC). As an underlying mechanism, ADC with a predisposed clonally inactivated Rb and p53 mutation and APOBEC mutation

Trial Details

NCT ID

NCT06830694

Phase

PHASE2

Sponsor

Se-Hoon Lee

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Atezolizumab, Etoposide, Carboplatin, Tarlatamab

Locations (sample)

• Seoul, Gangnam-gu, South Korea|37.566,126.9784

Key Eligibility Criteria

• Histologically confirmed SCLC and no prior systemic treatment for SCLC
• Patient initially diagnosed with activating EGFR mutation (L858R, Del 19) and treated with any kind of EGFR TKI.
• Confirmed SCLC transformation right after EGFR TKI treatment failure.
• Age ≥19 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →